Realize, Analyze, Engage (RAE): A Digital Tool to Support Recovery from Substance Use Disorder

Stephanie Carreiro, Melissa Taylor, Sloke Shrestha, Megan Reinhardt, Nicole Gilbertson, Premananda Indic, Stephanie Carreiro, Melissa Taylor, Sloke Shrestha, Megan Reinhardt, Nicole Gilbertson, Premananda Indic

Abstract

Background: Substance use disorders are a highly prevalent group of chronic diseases with devastating individual and public health consequences. Current treatment strategies suffer from high rates of relapse, or return to drug use, and novel solutions are desperately needed. Realize Analyze Engage (RAE) is a digital, mHealth intervention that focusses on real time, objective detection of high-risk events (stress and drug craving) to deploy just-in-time supportive interventions. The present study aims to (1) evaluate the accuracy and usability of the RAE system and (2) evaluate the impact of RAE on patient centered outcomes.

Methods: The first phase of the study will be an observational trial of N = 50 participants in outpatient treatment for SUD using the RAE system for 30 days. Accuracy of craving and stress detection algorithms will be evaluated, and usability of RAE will be explored via semi-structured interviews with participants and focus groups with SUD treatment clinicians. The second phase of the study will be a randomized controlled trial of RAE vs usual care to evaluate rates of return to use, retention in treatment, and quality of life.

Anticipated findings and future directions: The RAE platform is a potentially powerful tool to de-escalate stress and craving outside of the clinical milieu, and to connect with a support system needed most. RAE also aims to provide clinicians with actionable insight to understand patients' level of risk, and contextual clues for their triggers in order to provide more personalized recovery support.

Keywords: craving; digital diagnostics; digital health; digital therapeutics; mHealth; stress; substance use disorder; wearable.

Conflict of interest statement

CONFLICTS OF INTEREST Megan Reinhardt is the CEO of RAE Health and Nicole Gilbertson is the COO of RAE Health. They represent the small business partners in this small business innovation research award.

Figures

Figure 1.
Figure 1.
RAE System Architecture.
Figure 2.
Figure 2.
Garmin Vivosmart 4.
Figure 3.
Figure 3.
RAE Mobile App.
Figure 4.
Figure 4.
RAE Clinical Portal Home Screen.

References

    1. Substance Abuse and Mental Health Services Administration. Mental Health and Substance Use Disorders 2020. Available from: . Accessed 2021 Feb 15.
    1. Substance Abuse and Mental Health Services Administration (SAMHSA). Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health 2019. Available from: . Accessed 2021 Feb 15.
    1. Back SE, Gros DF, McCauley JL, Flanagan JC, Cox E, Barth KS, et al. Laboratory-induced cue reactivity among individuals with prescription opioid dependence. Addict Behav. 2014;39(8):1217–23.
    1. Pool ER, Sander D. Vulnerability to relapse under stress: insights from affective neuroscience. Swiss Med Wkly. 2019;149:w20151.
    1. Sinha R How does stress increase risk of drug abuse and relapse? Psychopharmacology. 2001;158(4):343–59.
    1. Preston KL, Epstein DH. Stress in the daily lives of cocaine and heroin users: relationship to mood, craving, relapse triggers, and cocaine use. Psychopharmacology. 2011;218(1):29–37.
    1. Sinha R, Catapano D, OʼMalley S. Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology. 1999;142(4):343–51.
    1. Sinha R Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008;1141:105–30.
    1. Brady KT, Sonne SC. The role of stress in alcohol use, alcoholism treatment, and relapse. Alcohol Res Health. 1999;23(4):263–71.
    1. Kavanagh DJ, Connor JP. Craving: a research update: editorial to a special issue. Addict Behav. 2013;38(2):1499–500.
    1. Tapper K Mindfulness and craving: effects and mechanisms. Clin Psychol Rev. 2018;59:101–17.
    1. Tiffany ST, Wray JM. The clinical significance of drug craving. Ann N Y Acad Sci. 2012;1248:1–17.
    1. Carreiro S, Chintha KK, Shrestha S, Chapman B, Smelson D, Indic P. Wearable sensor-based detection of stress and craving in patients during treatment for substance use disorder: A mixed methods pilot study. Drug Alcohol Depend. 2020;209:107929.
    1. Li W, Howard MO, Garland EL, McGovern P, Lazar M. Mindfulness treatment for substance misuse: A systematic review and meta-analysis. J Subst Abuse Treat. 2017;75:62–96.
    1. Glasner-Edwards S, Mooney LJ, Ang A, Garneau HC, Hartwell E, Brecht ML, et al. Mindfulness Based Relapse Prevention for Stimulant Dependent Adults: A Pilot Randomized Clinical Trial. Mindfulness. 2017;8(1):126–35.
    1. Ardame A, Bassaknejad S, Zargard Y, Rokni P, Sayyah M. Examine the Relationship between Mindfulness and Drug Craving in Addicts Undergoing Methadone Maintenance Treatment. Iran J Public Health. 2014;43(3):349–54.
    1. Bowen S, Chawla N, Collins SE, Witkiewitz K, Hsu S, Grow J, et al. Mindfulness-based relapse prevention for substance use disorders: a pilot efficacy trial. Subst Abus. 2009;30(4):295–305.
    1. Garland EL, Manusov EG, Froeliger B, Kelly A, Williams JM, Howard MO. Mindfulness-oriented recovery enhancement for chronic pain and prescription opioid misuse: results from an early-stage randomized controlled trial. J Consult Clin Psychol. 2014;82(3):448–59.
    1. Garbarino M, Lai M, Bender D, Picard RW, Tognetti S, editors. Empatica E3—A wearable wireless multi-sensor device for real-time computerized biofeedback and data acquisition. In Proceedings of 2014 4th International Conference on Wireless Mobile Communication and Healthcare-Transforming Healthcare Through Innovations in Mobile and Wireless Technologies (MOBIHEALTH); 2014 3–5 Nov; Athens, Greece.
    1. Hunkin H, King DL, Zajac IT. Perceived acceptability of wearable devices for the treatment of mental health problems. J Clin Psychol. 2020;76(6):987–1003.
    1. Loncar-Turukalo T, Zdravevski E, Machado da Silva J, Chouvarda I, Trajkovik V. Literature on Wearable Technology for Connected Health: Scoping Review of Research Trends, Advances, and Barriers. J Med Internet Res. 2019;21(9):e14017.
    1. Indic P, Murray G, Maggini C, Amore M, Meschi T, Borghi L, et al. Multi-scale motility amplitude associated with suicidal thoughts in major depression. PLoS One. 2012;7(6):e38761.
    1. Fletcher RR, Tam S, Omojola O, Redemske R, Kwan J. Wearable sensor platform and mobile application for use in cognitive behavioral therapy for drug addiction and PTSD. Annu Int Conf IEEE Eng Med Biol Soc. 2011;2011:1802–5.
    1. Hernandez J, Morris RR, Picard RW, editors. Call center stress recognition with person-specific models. In International Conference on Affective Computing and Intelligent Interaction. New York (US): Springer; 2011. p. 125–34.
    1. Healey JA, Picard RW. Detecting stress during real-world driving tasks using physiological sensors. IEEE Trans Intell Transp Syst. 2005;6(2):156–66.
    1. Sarkis RA, Thome-Souza S, Poh MZ, Llewellyn N, Klehm J, Madsen JR, et al. Autonomic changes following generalized tonic clonic seizures: An analysis of adult and pediatric patients with epilepsy. Epilepsy Res. 2015;115:113–8.
    1. Carreiro S, Fang H, Zhang J, Wittbold K, Weng S, Mullins R, et al. iMStrong: Deployment of a Biosensor System to Detect Cocaine Use. J Med Syst. 2015;39(12):186.
    1. Carreiro S, Wittbold K, Indic P, Fang H, Zhang J, Boyer EW. Wearable Biosensors to Detect Physiologic Change During Opioid Use. J Med Toxicol. 2016;12(3):255–62.
    1. Inui T, Kohno H, Kawasaki Y, Matsuura K, Ueda H, Tamura Y, et al. Use of a Smart Watch for Early Detection of Paroxysmal Atrial Fibrillation: Validation Study. JMIR Cardio. 2020;4(1):e14857.
    1. Isakadze N, Martin SS. How useful is the smartwatch ECG? Trends Cardiovasc Med. 2020;30(7):442–8.
    1. Falter M, Budts W, Goetschalckx K, Cornelissen V, Buys R. Accuracy of Apple Watch Measurements for Heart Rate and Energy Expenditure in Patients With Cardiovascular Disease: Cross-Sectional Study. JMIR Mhealth Uhealth. 2019;7(3):e11889.
    1. Carreiro S, Newcomb M, Leach R, Ostrowski S, Boudreaux ED, Amante D. Current reporting of usability and impact of mHealth interventions for substance use disorder: A systematic review. Drug and Alcohol Dependence. 2020;215:108201.
    1. Gustafson DH, McTavish FM, Chih MY, Atwood AK, Johnson RA, Boyle MG, et al. A smartphone application to support recovery from alcoholism: a randomized clinical trial. JAMA Psychiatry. 2014;71(5):566–72.
    1. Leonard NR, Silverman M, Sherpa DP, Naegle MA, Kim H, Coffman DL, et al. Mobile Health Technology Using a Wearable Sensorband for Female College Students With Problem Drinking: An Acceptability and Feasibility Study. JMIR Mhealth Uhealth. 2017;5(7):e90.
    1. Monney G, Penzenstadler L, Dupraz O, Etter J-F, Khazaal Y. mHealth App for Cannabis Users: Satisfaction and Perceived Usefulness. Front Psychiatry. 2015;6:120.
    1. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403–9.
    1. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med. 1998;46(12):1569–85.
    1. Skevington SM, McCrate FM. Expecting a good quality of life in health: assessing people with diverse diseases and conditions using the WHOQOL-BREF. Health Expectations. 2012;15(1):49–62.
    1. Cameron IM, Cunningham L, Crawford JR, Eagles JM, Eisen SV, Lawton K, et al. Psychometric properties of the BASIS-24© (Behaviour and Symptom Identification Scale-Revised) Mental Health Outcome Measu re. Int J Psychiatry Clin Pract. 2007;11(1):36–43.
    1. Eisen SV, Gerena M, Ranganathan G, Esch D, Idiculla T. Reliability and validity of the BASIS-24 Mental Health Survey for Whites, African-Americans, and Latinos. J Behav Health Serv Res. 2006;33(3):304–23.
    1. Cacciola JS, Alterman AI, Dephilippis D, Drapkin ML, Valadez C Jr., Fala NC, et al. Development and initial evaluation of the Brief Addiction Monitor (BAM). J Subst Abuse Treat. 2013;44(3):256–63.
    1. Picard RW, Liu KK. Relative subjective count and assessment of interruptive technologies applied to mobile monitoring of stress. Int J Hum-Comput Stud. 2007;65(4):361–75.
    1. Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J 2020;17(1):26.
    1. Volkow ND. Collision of the COVID-19 and Addiction Epidemics. Ann Intern Med. 2020. doi: 10.7326/M20-1212

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi